Studies Find Merlin CP-GEP Test Improved Melanoma Risk Stratification
Two peer-reviewed studies demonstrate superior risk stratification compared to traditional clinicopathologic features and competitor testing.
Two peer-reviewed studies demonstrate superior risk stratification compared to traditional clinicopathologic features and competitor testing.
A new technology in molecular imaging and pathology is paving the way for a more objective approach to melanoma diagnosis.
DecisionDx-Melanoma was shown to provide significant, independent risk stratification of patients with cutaneous melanoma, which may help inform more personalized melanoma patient management decisions.
Roche has announced the launch of the PRAME Antibody to identify PRAME protein expression with suspected melanoma.
Read MoreProscia released study results on new AI that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.
Read MoreUnilabs and Proscia have announced that the diagnostic group has chosen Proscia’s DermAI skin pathology solution.
Read MoreInterVenn’s new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
Read MoreResearchers have discovered blood biomarkers that can help identify if someone suffering from Melanoma can benefit from immune checkpoint inhibitors.
Read MoreFoundationOne CDx is used as a companion diagnostic for two groups of FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies.
Read MoreResearchers used deep learning framework to transform microscopy images of intact skin into histochemically stained sections imaged on microscope slides.
Read MoreProscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.
Read MoreCastle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.
Read MoreThe blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreThe launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.
Read MoreThe highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor ipilimumab.
Read MoreThe Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read MoreBluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read MoreNanopipettes with zwitterionic membranes may offer improved monitoring of changes in pH surrounding living cells, which can indicate traits of invasive cancer cells and their response to treatment.
Read More